UPenn Perelman School of Medicine: Single-Dose Gene Therapy is Potentially Life-Changing for Adults With Hemophilia B
September 26, 2024
September 26, 2024
UNIVERSITY CITY, Pennsylvania, Sept. 26 (TNSres) -- The University of Pennsylvania's Perelman School of Medicine issued the following news release:
* * *
Study results formed the basis of the therapy's FDA approval in April 2024
* * *
PHILADELPHIA - Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent after a single infusion of gene therapy, according to the results of an international Phase III clinic . . .
* * *
Study results formed the basis of the therapy's FDA approval in April 2024
* * *
PHILADELPHIA - Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent after a single infusion of gene therapy, according to the results of an international Phase III clinic . . .